RYAM: Adjusted EBITDA rose 30% sequentially as tariffs idled Temiscaming and delayed the strategic review

What happened

RYAM’s third-quarter adjusted EBITDA, a measure of operating earnings before interest, taxes, depreciation and amortization, rose 30% sequentially to $52 million. A $221 million non-cash impairment contributed to a $229 million reported loss. Tariffs idled Temiscaming production and pushed the strategic-review conclusion target to Q1 2027.

Confirmed

Global impact / market context

The improved adjusted EBITDA points to stronger operating earnings than in the prior quarter, but the reported loss and idle production show significant pressure remains. Tariff-related downtime can reduce sales and leave costs spread over less output, while a delayed review postpones clarity on strategic decisions.

Analyst inference

The figures present a mixed picture: sequential operating earnings improved, yet the impairment drove a large reported loss and tariffs disrupted production. The impairment is a non-cash accounting charge, so it affects reported results without itself representing a cash payment; the production halt may still affect cash generation.

Analyst inference

What to watch

1. Check subsequent updates for whether Temiscaming resumes production; a longer shutdown could constrain output and sales, while restarting may add production and operating costs. Analyst inference
2. Watch for the strategic-review conclusion, now targeted for Q1 2027; the article gives no outcome, so any decision or timing change remains uncertain. Confirmed
3. Compare later adjusted EBITDA with reported results and cash generation to see whether operating improvement continues and whether accounting charges obscure underlying performance. Analyst inference

Evidence

• Original source link unavailable